Adamax
- Category
- Brain & Cognition
- Administration routes
- Nasal
- Regulatory status
- Not FDA-approved
What it is
Adamax is a synthetic Semax analog with an added adamantane group for stability, marketed for cognitive enhancement and neuroprotection. The human case is weak: BDNF upregulation and neuroprotection are only low-confidence, and cognitive gains remain speculative. No human safety data exist for Adamax itself, and safety from Semax may not hold for this modified molecule. Not an approved drug in the US; supply is unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(6)
BDNF Upregulation
LowSemax rodent studies show BDNF and TrkB increases; no Adamax-specific data exists yet.
Enhanced Blood-Brain Barrier Penetration
SpeculativeMechanism-based only; adamantane conjugation aids CNS delivery but no Adamax uptake data exists.
Extended Duration of Action
SpeculativeMechanism-based only; acetylation may resist degradation, but no Adamax stability data exists.
Evidence limits
- Evidence Level
- Preclinical
Adamax has ZERO published peer-reviewed studies as of March 2026. All evidence is extrapolated from extensive Semax research (50+ preclinical studies, several human clinical trials in Russia for stroke therapy) and from general adamantane-modification pharmacology. The parent compound Semax has strong preclinical evidence for BDNF upregulation, neuroprotection, and cognitive effects in animal models, plus human clinical use in Russia/Ukraine for stroke recovery. However, Adamax's specific efficacy, optimal dosing, and safety profile in humans remain entirely unvalidated by published research.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(12)
Risks = level of concern: High · Moderate · Low · Theoretical
No published human safety or toxicology data exists for Adamax specifically
HighAll safety extrapolations are from the parent compound Semax, which may not fully apply to the modified molecule
HighAnecdotal reports of mild headaches and dizziness, typically dose-dependent
LowNasal irritation with intranasal administration
LowTemporary mood or cognition changes during initial use
LowInsomnia reported when administered late in the day
LowRare allergic reactions reported anecdotally
LowNo long-term safety data available for chronic use
HighQuality and purity vary among unregulated products sold online; not pharmaceutical-grade manufacturing
HighPotential for unknown drug interactions due to lack of formal pharmacological profiling
ModerateTheoretical risk of excessive BDNF signaling with chronic high-dose use (no data to quantify)
TheoreticalNo established antidote or reversal protocol in case of adverse reaction
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.